We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » NeuroVive Extends Collaboration with French Hospital, Hospices Civils de Lyon

NeuroVive Extends Collaboration with French Hospital, Hospices Civils de Lyon

June 4, 2014

Swedish mitochondrial drugmaker NeuroVive said Tuesday it is extending its collaboration with French hospital Hospices Civils de Lyon (HCL), which broadens the scope of NeuroVive’s cardiovascular business and will help maintain its leading position in mitochondrial medicine.

The new pact, designated OPeRA (Organ Protection & Replacement Institute), includes pre-clinical research and development programs as well as clinical phase II programs, giving NeuroVive access to medical technology and patient groups for the evaluation of its drug candidates, the company said.

NeuroVive began its collaboration, and the European Phase III study of its heart attack drug CicloMulsion, with HCL in 2011.

The OPeRA program has received financial backing from the French government and from several companies, including NeuroVive, through 2018. The program incorporates different medical areas and is based on programs in diabetes, metabolic disorders, transplantation, cardiovascular diseases, inflammatory conditions and infectious diseases, NeuroVive said.

By partnering with the OPeRA program, NeuroVive can study its cyclophilin inhibitors, such as CicloMulsion, and new drug candidates in various animal models for efficacy against cardiovascular diseases before testing them in humans, the company noted.

The OPeRA program partnership not only gives NeuroVive the rights to the projects directly covered by the collaboration with HCL, but also provides the company access to research findings across all areas of the program, which could lead to commercial development, it said. — Kellen Owings

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.

Pharmaceuticals Research and Development Commercial Operations

Upcoming Events

  • 19Jan

    Pharmaceutical Quality Risk Management: Navigating the Intersection Between Regulatory Requirements & Risk Management

  • 21Jan

    Virtual MDSAP Audits in the Era of COVID-19: What to Know and Do to Pass Virtual Audits

  • 26Jan

    Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

  • 27Jan

    Medical Device Clinical Trials in China: Latest Regulatory Developments

  • 27Jan

    FDA’s Response to COVID-19: Fundamentals of Obtaining Emergency Use Authorizations

  • 09Feb

    Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Regeneron logo

    U.S. Government Orders More Supplies of Regeneron’s COVID-19 Antibody Cocktail

  • Siemens Healthineers logo

    Siemens Healthineers COVID Test Gets Additional Sampling Method Clearance

  • COVID-19  Clinical Trial

    Synairgen Initiates Dosing in Late-Stage Trial of Inhaled COVID-19 Therapy

  • Verona Pharma logo

    Verona Pharma Ends Enrollment in Inhaler-Administered COVID-19 Drug Pilot

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing